Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2016-01-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.5b00832PMID 26317591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

  2016cited by this paper
• Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.

  2015cited by this paper
• Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.

  2015cited by this paper
• Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.

  2015cited by this paper
• Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.

  2015cited by this paper
• The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry

  2015cited by this paper
• Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.

  2015cited by this paper
• Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis

  2015cited by this paper
• Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.

  2015cited by this paper
• Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

  2015cited by this paper
• Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.

  2015cited by this paper
• Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia

  2014cited by this paper
• Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant

  2014cited by this paper
• Hypnotics in insomnia: the experience of zolpidem.

  2014cited by this paper
• Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.

  2014cited by this paper
• Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism

  2014cited by this paper
• GPCR structures in drug design, emerging opportunities with new structures.

  2014cited by this paper
• Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs

  2014cited by this paper
• Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

  2014cited by this paper
• Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement.

  2014cited by this paper
• Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist

  2014cited by this paper
• Entry‐into‐humans study with ACT‐462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant

  2014cited by this paper
• Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.

  2014cited by this paper
• Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

  2013cited by this paper
• The Generation, Detection, and Effects of Reactive Drug Metabolites

  2013cited by this paper
• Validating therapeutic targets through human genetics

  2013cited by this paper
• In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving

  2013cited by this paper
• Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition

  2013cited by this paper
• Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans

  2013cited by this paper
• Zolpidem and driving impairment--identifying persons at risk.

  2013cited by this paper
• Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist

  2013cited by this paper
• Demystifying brain penetration in central nervous system drug discovery. Miniperspective.

  2013cited by this paper
• Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).

  2013cited by this paper
• The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.

  2012cited by this paper
• Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.

  2012cited by this paper
• Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies.

  2012cited by this paper
• Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

  2012cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

  2012cited by this paper
• Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist

  2012cited by this paper
• Orexin receptor antagonism for treatment of insomnia

  2012cited by this paper
• Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone

  2012cited by this paper
• Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial

  2012cited by this paper
• Subjective sleeping problems and selfreported sleep length during four seasons in arctic Northern Norway

  2011cited by this paper
• Orexin receptors: pharmacology and therapeutic opportunities.

  2011cited by this paper
• Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

  2011cited by this paper
• Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal.

  2011cited by this paper
• Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

  2011cited by this paper
• Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.

  2011cited by this paper
• Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.

  2011cited by this paper
• Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.

  2011cited by this paper
• Disposition and Metabolism of [14C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans

  2011cited by this paper
• Orexin Receptor Antagonism, a New Sleep‐Promoting Paradigm: An Ascending Single‐Dose Study With Almorexant

  2010cited by this paper
• Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics

  2010cited by this paper
• Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.

  2010cited by this paper
• The hyperarousal model of insomnia: a review of the concept and its evidence.

  2010cited by this paper
• Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

  2010cited by this paper
• Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N,N‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats

  2009cited by this paper
• The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers.

  2009cited by this paper
• The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies.

  2009cited by this paper
• Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.

  2009cited by this paper
• Essentials of Polysomnography: A Training Guide and Reference for Sleep Technicians

  2009cited by this paper
• N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists.

  2008cited by this paper
• Proline bis-amides as potent dual orexin receptor antagonists.

  2008cited by this paper
• Orexin receptor antagonists: medicinal chemistry and therapeutic potential.

  2008cited by this paper
• Promotion of sleep by targeting the orexin system in rats, dogs and humans

  2007cited by this paper
• Insomnia market

  2006cited by this paper
• One rare side effect of zolpidem--sleepwalking: a case report.

  2005cited by this paper
• Characterisation of the binding of [3H]‐SB‐674042, a novel nonpeptide antagonist, to the human orexin‐1 receptor

  2004cited by this paper
• Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists.

  2004cited by this paper
• Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.

  2003cited by this paper
• N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist.

  2003cited by this paper
• Tetrahydroisoquinolines as Orexin Receptor Antagonists: Strategies for Lead Optimization by Solution‐Phase Chemistry

  2003cited by this paper
• SB‐334867‐A: the first selective orexin‐1 receptor antagonist

  2001cited by this paper
• 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.

  2001cited by this paper
• Reduced Number of Hypocretin Clinical Study Neurons in Human Narcolepsy

  2000cited by this paper
• Hypocretin (orexin) deficiency in human narcolepsy.

  2000cited by this paper
• Central nervous system side effects associated with zolpidem treatment.

  2000cited by this paper
• Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement

  2000cited by this paper
• The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.

  1999cited by this paper
• Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

  1999cited by this paper
• The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

  1998cited by this paper
• Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

  1998cited by this paper
• Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

  1998cited by this paper
• Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial.

  1996cited by this paper
• Economic effects of insomnia.

  1994cited by this paper

• Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer’s disease

  2026cites this paper
• Orexin Receptor Antagonists and Insomnia

  2025cites this paper
• Diagnosis, Treatment, and Associated Outcomes of Later-Life Insomnia: A Narrative Review.

  2025cites this paper
• Highly regioselective alkylation of 2-aryl-1,2,3-triazoles with maleimides through ortho-C H functionalization

  2025cites this paper
• Nicotine replacement therapy: insights into the mechanisms and potential of nicotine receptor pathway.

  2025cites this paper
• Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer's disease and Parkinson's disease: Therapeutic avenue of Dual OXR Antagonist (DORA).

  2025cites this paper
• Syntheses and preclinical evaluations of 11C-labeled radioligands for imaging brain orexin-1 and orexin-2 receptors with positron emission tomography.

  2025cites this paper
• G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

  2024cites this paper
• Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds.

  2024cites this paper
• International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology

  2024cites this paper
• Harnessing conformational drivers in drug design.

  2024cites this paper
• Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials.

  2024cites this paper
• Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

  2024cites this paper
• The Orexinergic System: Neurobiology and Clinical Implications

  2024cites this paper
• Synthesis and Characterization of Novel Radioiodinated Triazole-Pyrolidine Derivative to Detect Orexin 2 Receptor in the Brain.

  2023cites this paper
• Synthesis and clinical application of new drugs approved by FDA in 2022

  2023cites this paper
• A phase 1 study of dimdazenil to evaluate the pharmacokinetics, food effect and safety in Chinese healthy subjects

  2023cites this paper
• Exploratory Process Development of a High-Temperature Thermal (3 + 2) Cycloaddition in Continuous Flow for the Synthesis of Seltorexant

  2023cites this paper
• The Present and Future of Synthetic Orexin Receptor Agonists.

  2023cites this paper
• New drug approvals for 2022: Synthesis and clinical applications

  2023cites this paper
• Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis

  2023cites this paper
• Azulene as a biphenyl mimetic in orexin/hypocretin receptor agonists.

  2023cites this paper
• Plants Alkaloids Based Compound as Therapeutic Potential for Neurodegenerative

  2023cites this paper
• Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: from animal to clinical studies.

  2023cites this paper
• Physiological Role of Orexin/Hypocretin in the Human Body in Motivated Behavior: A Comprehensive Review

  2023cites this paper
• Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder

  2022cites this paper
• Orexin Receptor Antagonists and Insomnia

  2022cites this paper
• Interaction between the Human OX2 Orexin Receptor and Suvorexant and Some of Its Analogues: SAPT (DFT) Interaction Energy Decomposition Analysis.

  2022cites this paper
• Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging.

  2022cites this paper
• The Orexin receptors: Structural and anti-tumoral properties

  2022cites this paper
• Hypothalamic stress systems in mood disorders.

  2021cites this paper
• Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.

  2021cites this paper
• G protein-coupled receptors: structure- and function-based drug discovery

  2021cites this paper
• The dual orexin receptor antagonist DORA-22 improves mild stress-induced sleep disruption during the natural sleep phase of nocturnal rats.

  2021cites this paper
• Chemogenomics for drug discovery: clinical molecules from open access chemical probes

  2021cites this paper
• Asymmetric synthesis of six tetrahydroisoquinoline natural products through α-amination of an aldehyde

  2021cites this paper
• MC-100093, a Novel β-Lactam Glutamate Transporter-1 Enhancer Devoid of Antimicrobial Properties, Attenuates Cocaine Relapse in Rats

  2021cites this paper
• Synthesis and biological evaluation of novel 18F-labeled phenylbenzofuran-2-carboxamide derivative for detection of orexin 1 receptor in the brain.

  2021cites this paper
• MC-100093, a novel β-lactam GLT-1 enhancer devoid of antimicrobial properties attenuates cocaine relapse in rats

  2021cites this paper
• Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions

  2021cites this paper
• Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton.

  2021cites this paper
• Orexin receptors in GtoPdb v.2021.3.

  2021cites this paper
• Discovery of novel orexin receptor antagonists using a 1,3,5-trioxazatriquinane bearing multiple effective residues (TriMER) library.

  2021cites this paper
• The Role of Orexin in Alzheimer Disease: From Sleep-wake Disturbance to Therapeutic Target.

  2021cites this paper
• Emerging therapeutic targets for narcolepsy

  2021cites this paper
• Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists

  2020cites this paper
• Cyclic tailor-made amino acids in the design of modern pharmaceuticals.

  2020cites this paper
• Structure-based development of a subtype-selective orexin 1 receptor antagonist

  2020cites this paper
• Acute Cognitive Effects of the Hypocretin Receptor Antagonist Almorexant Relative to Zolpidem and Placebo: A Randomized Clinical Trial.

  2020cites this paper
• Biphasic Feature of Placebo Response in Primary Insomnia: Pooled Analysis of Data from Randomized Controlled Clinical Trials of Orexin Receptor Antagonists.

  2020cites this paper
• The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts.

  2020cites this paper
• Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

  2020cites this paper
• A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging

  2020cites this paper
• Crystal structure of the Orexin-1 receptor in complex with Compound 16

  2020cites this paper
• Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

  2020cites this paper
• Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats

  2020cites this paper
• Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis

  2019cites this paper
• Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal

  2019cites this paper
• Determinants of Orexin Receptor Binding and Activation—A Molecular Dynamics Study

  2019cites this paper
• Structure–Activity Relationships of 1‐Benzoylazulenes at the OX1 and OX2 Orexin Receptors

  2019cites this paper
• Pharmacology of Orexin/Hypocretin Receptors

  2019cites this paper
• Synthesis and biological evaluation of F-18 labeled tetrahydroisoquinoline derivatives targeting orexin 1 receptor.

  2019cites this paper
• Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats

  2019cites this paper
• Molecular modeling technology studies of novel pyrazoylethylbenzamide derivatives as selective orexin receptor 1 antagonists

  2019cites this paper
• Highly Regioselective Radical Transformation of N-Sulfonyl-1,2,3-triazoles in Air.

  2019cites this paper
• Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.

  2019cites this paper
• Neurochemical and Behavioral Outcomes of Intranasal Orexin Administration in Young and Aged Animals

  2019cites this paper
• Orexin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases

  2019cites this paper
• Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target.

  2019cites this paper
• Molecular evolution of G protein-coupled receptors – insights into the orexin system

  2019cites this paper
• Synthesis and characterization of a novel 18F-labeled 2,5-diarylnicotinamide derivative targeting orexin 2 receptor.

  2019cites this paper
• Small-Molecule Ligands as Challenge for Positron Emission Tomography of Peptide Receptors in Neurons and Microglia of the Brain

  2019influential citation
• Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine

  2018cites this paper
• Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations

  2018cites this paper
• Rhodium‐Catalyzed ortho‐Cyanation of 2‐Aryl‐1,2,3‐triazole: An Alternative Approach to Suvorexant

  2018cites this paper
• Stapled truncated orexin peptides as orexin receptor agonists

  2018cites this paper
• Discovery of OX1 and OX2 orexin receptor ligands

  2018cites this paper
• Rôle antitumoral de l'orexine A et des ligands biaisés dans les cancers digestifs. Impact sur le trafic intracellulaire d'OX1R

  2018cites this paper
• The Role of Melanin-Concentrating Hormone in the Regulation of the Sleep/Wake Cycle: Sleep Promoter or Arousal Modulator?

  2018cites this paper
• The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role

  2018cites this paper
• Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26

  2018cites this paper
• An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics

  2018cites this paper
• Azulene-based compounds for targeting orexin receptors.

  2018cites this paper
• Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin‐A (hypocretin‐1)

  2018cites this paper
• Synthesis of azulene-based compounds for targeting orexin receptors

  2018cites this paper
• Computational analysis of orexin receptors and their interactions with natural and synthetic ligands

  2018cites this paper
• The Literature of Heterocyclic Chemistry, Part XVI, 2016

  2018cites this paper
• Palladium-catalyzed direct C–H ethoxycarbonylation of 2-aryl-1,2,3-triazoles and efficient synthesis of suvorexant

  2018cites this paper
• Spirocyclic Scaffolds in Drug Discovery

  2017cites this paper
• Privileged heterocycles: bioactivity and synthesis of 1,9-diazaspiro[5.5]undecane-containing compounds

  2017cites this paper
• Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.

  2017cites this paper
• Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity

  2017cites this paper
• Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Effects of Suvorexant , a Dual Orexin / Hypocretin Receptor Antagonist , on Impulsive Behavior Associated with Cocaine

  2017cites this paper
• Orexin research: patent news from 2016

  2017cites this paper
• Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.

  2017cites this paper
• Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.

  2017cites this paper
• Hypocretin (Orexin) in Models of Cocaine Addiction

  2017cites this paper
• Orexin Receptor Antagonists

  2017cites this paper
• Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.

  2017cites this paper